TransMedics Historical Income Statement

TMDX Stock

USD 76.04 3.30 4.16%

Historical analysis of TransMedics income statement accounts such as Total Other Income Expense Net of 2.2 M, Interest Income of 13.1 M, Depreciation And Amortization of 8.6 M or Total Revenue of 253.7 M can show how well TransMedics Group performed in making a profits. Evaluating TransMedics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of TransMedics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining TransMedics Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether TransMedics Group is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TransMedics Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

About TransMedics Income Statement Analysis

TransMedics Group Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to TransMedics shareholders. The income statement also shows TransMedics investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

TransMedics Income Statement Chart

At this time, TransMedics' Reconciled Depreciation is fairly stable compared to the past year.

Selling General Administrative Research Development Total Operating Expenses Total Other Income Expense Net Total Revenue

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Total Revenue

Total revenue comprises all receipts TransMedics Group generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from TransMedics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into TransMedics Group current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TransMedics Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

At this time, TransMedics' Reconciled Depreciation is fairly stable compared to the past year.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	60.6M	96.7M	182.8M	192.0M
Research Development	22.3M	26.8M	36.1M	22.2M

Total Operating Expenses Research Development

TransMedics income statement Correlations

	Interest Expense	Selling General Administrative	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Income	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Ebitda	Cost Of Revenue	Income Tax Expense	Selling And Marketing Expenses	Reconciled Depreciation	Non Operating Income Net Other
Interest Expense		0.97	-0.56	-0.72	0.18	0.8	0.96	-0.35	0.18	-0.27	-0.98	0.92	0.95	0.95	0.95	0.96	0.55	0.94	-0.96	0.17	0.95	0.87
Selling General Administrative	0.97		-0.54	-0.69	0.2	0.83	1.0	-0.32	0.24	-0.23	-0.94	0.94	1.0	0.99	0.99	1.0	0.57	0.98	-0.92	0.25	0.99	0.89
Operating Income	-0.56	-0.54		0.97	0.7	-0.65	-0.54	0.95	0.58	0.93	0.62	-0.27	-0.54	-0.44	-0.46	-0.48	0.35	-0.38	0.5	-0.63	-0.54	-0.26
Net Income From Continuing Ops	-0.72	-0.69	0.97		0.55	-0.74	-0.69	0.9	0.47	0.86	0.77	-0.45	-0.69	-0.6	-0.62	-0.64	0.16	-0.55	0.66	-0.6	-0.69	-0.43
Ebit	0.18	0.2	0.7	0.55		-0.1	0.19	0.86	0.93	0.9	-0.07	0.49	0.18	0.31	0.28	0.26	0.9	0.37	-0.19	-0.66	0.18	0.46
Research Development	0.8	0.83	-0.65	-0.74	-0.1		0.83	-0.5	-0.09	-0.44	-0.83	0.67	0.83	0.8	0.81	0.81	0.26	0.76	-0.76	0.49	0.84	0.79
Total Operating Expenses	0.96	1.0	-0.54	-0.69	0.19	0.83		-0.31	0.23	-0.23	-0.93	0.93	1.0	0.99	1.0	1.0	0.57	0.98	-0.91	0.29	1.0	0.88
Income Before Tax	-0.35	-0.32	0.95	0.9	0.86	-0.5	-0.31		0.79	1.0	0.45	-0.01	-0.32	-0.2	-0.23	-0.25	0.57	-0.14	0.32	-0.7	-0.32	-0.01
Total Other Income Expense Net	0.18	0.24	0.58	0.47	0.93	-0.09	0.23	0.79		0.84	-0.03	0.53	0.22	0.34	0.3	0.29	0.87	0.4	-0.16	-0.67	0.2	0.5
Net Income	-0.27	-0.23	0.93	0.86	0.9	-0.44	-0.23	1.0	0.84		0.37	0.08	-0.23	-0.11	-0.15	-0.16	0.63	-0.05	0.24	-0.71	-0.24	0.07
Net Interest Income	-0.98	-0.94	0.62	0.77	-0.07	-0.83	-0.93	0.45	-0.03	0.37		-0.85	-0.92	-0.91	-0.91	-0.92	-0.44	-0.89	0.95	-0.25	-0.93	-0.82
Interest Income	0.92	0.94	-0.27	-0.45	0.49	0.67	0.93	-0.01	0.53	0.08	-0.85		0.92	0.96	0.95	0.95	0.79	0.98	-0.87	-0.08	0.91	0.94
Depreciation And Amortization	0.95	1.0	-0.54	-0.69	0.18	0.83	1.0	-0.32	0.22	-0.23	-0.92	0.92		0.99	0.99	0.99	0.56	0.97	-0.91	0.31	1.0	0.87
Total Revenue	0.95	0.99	-0.44	-0.6	0.31	0.8	0.99	-0.2	0.34	-0.11	-0.91	0.96	0.99		1.0	1.0	0.66	1.0	-0.9	0.2	0.99	0.91
Gross Profit	0.95	0.99	-0.46	-0.62	0.28	0.81	1.0	-0.23	0.3	-0.15	-0.91	0.95	0.99	1.0		1.0	0.63	0.99	-0.9	0.24	0.99	0.9
Other Operating Expenses	0.96	1.0	-0.48	-0.64	0.26	0.81	1.0	-0.25	0.29	-0.16	-0.92	0.95	0.99	1.0	1.0		0.62	0.99	-0.9	0.24	0.99	0.9
Ebitda	0.55	0.57	0.35	0.16	0.9	0.26	0.57	0.57	0.87	0.63	-0.44	0.79	0.56	0.66	0.63	0.62		0.71	-0.54	-0.44	0.55	0.74
Cost Of Revenue	0.94	0.98	-0.38	-0.55	0.37	0.76	0.98	-0.14	0.4	-0.05	-0.89	0.98	0.97	1.0	0.99	0.99	0.71		-0.89	0.13	0.97	0.93
Income Tax Expense	-0.96	-0.92	0.5	0.66	-0.19	-0.76	-0.91	0.32	-0.16	0.24	0.95	-0.87	-0.91	-0.9	-0.9	-0.9	-0.54	-0.89		-0.18	-0.9	-0.82
Selling And Marketing Expenses	0.17	0.25	-0.63	-0.6	-0.66	0.49	0.29	-0.7	-0.67	-0.71	-0.25	-0.08	0.31	0.2	0.24	0.24	-0.44	0.13	-0.18		0.33	-0.05
Reconciled Depreciation	0.95	0.99	-0.54	-0.69	0.18	0.84	1.0	-0.32	0.2	-0.24	-0.93	0.91	1.0	0.99	0.99	0.99	0.55	0.97	-0.9	0.33		0.86
Non Operating Income Net Other	0.87	0.89	-0.26	-0.43	0.46	0.79	0.88	-0.01	0.5	0.07	-0.82	0.94	0.87	0.91	0.9	0.9	0.74	0.93	-0.82	-0.05	0.86

Click cells to compare fundamentals

TransMedics Account Relationship Matchups

TransMedics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	4.4M	4.0M	3.9M	3.7M	10.8M	11.3M
Selling General Administrative	21.5M	24.2M	38.3M	51.7M	119.6M	125.5M
Operating Income	(29.6M)	(26.4M)	(39.4M)	(31.4M)	(28.7M)	(30.2M)
Net Income From Continuing Ops	(33.5M)	(28.7M)	(44.2M)	(36.2M)	(35.8M)	(37.6M)
Ebit	(29.6M)	(24.7M)	(41.1M)	(33.2M)	(15.8M)	(16.6M)
Research Development	19.9M	18.8M	22.3M	26.8M	36.1M	22.2M
Total Operating Expenses	43.5M	43.0M	60.6M	96.7M	182.8M	192.0M
Income Before Tax	(33.5M)	(28.7M)	(44.2M)	(36.2M)	(26.7M)	(28.0M)
Total Other Income Expense Net	(3.9M)	(2.3M)	(4.8M)	(4.7M)	2.1M	2.2M
Net Income Applicable To Common Shares	(33.5M)	(28.7M)	(44.2M)	(36.2M)	(32.6M)	(34.2M)
Net Income	(33.5M)	(28.7M)	(44.2M)	(36.2M)	(25.0M)	(26.3M)
Net Interest Income	(4.4M)	(4.0M)	(3.9M)	(3.7M)	(8.2M)	(7.8M)
Depreciation And Amortization	790K	1.6M	2.6M	4.2M	8.2M	8.6M
Total Revenue	23.6M	25.6M	30.3M	93.5M	241.6M	253.7M
Gross Profit	13.9M	16.6M	21.2M	65.3M	154.1M	161.8M
Other Operating Expenses	53.2M	52.0M	69.7M	124.9M	270.4M	283.9M
Ebitda	(28.8M)	(23.2M)	(38.5M)	(29.0M)	(7.6M)	(8.0M)
Cost Of Revenue	9.7M	9.0M	9.1M	28.2M	87.5M	91.9M
Selling And Marketing Expenses	2.1M	931K	8.6M	18.2M	2.1M	2.0M
Reconciled Depreciation	1.2M	1.6M	1.8M	3.5M	5.9M	6.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TransMedics Historical Income Statement

About TransMedics Income Statement Analysis

TransMedics Income Statement Chart

Total Operating Expenses

Total Revenue

TransMedics income statement Correlations

TransMedics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

TransMedics income statement Accounts

Also Currently Popular

Additional Tools for TransMedics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Selling General Administrative
Depreciation And Amortization	+ 1.0	Selling General Administrative
Other Operating Expenses	+ 1.0	Selling General Administrative
Depreciation And Amortization	+ 1.0	Total Operating Expenses
Gross Profit	+ 1.0	Total Operating Expenses
Other Operating Expenses	+ 1.0	Total Operating Expenses

Net Interest Income	- 0.98	Interest Expense
Income Tax Expense	- 0.96	Interest Expense
Net Interest Income	- 0.94	Selling General Administrative
Reconciled Depreciation	- 0.93	Net Interest Income
Net Interest Income	- 0.93	Total Operating Expenses
Other Operating Expenses	- 0.92	Net Interest Income